Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1886408 | 0.86 | CYP1A2 (1.00) | CYP1A2HSD17B10TAS2R38MEN1MAPT | |
| SCHEMBL9453941 | 0.85 | MEN1 (0.77) | CYP1A2HSD17B10MEN1MAPTKMT2A | |
| SCHEMBL30557461 | 0.85 | MEN1 (0.77) | CYP1A2HSD17B10MEN1MAPTKMT2A | |
| SCHEMBL2865596 | 0.83 | CYP1A2 (0.69) | CYP1A2HSD17B10MEN1MAPTKMT2A | |
| SCHEMBL27971555 | 0.81 | HSD17B10 (0.62) | CYP1A2HSD17B10MEN1KMT2ANPSR1 | |
| SCHEMBL25202109 | 0.80 | CYP1A2 (0.65) | CYP1A2HSD17B10MEN1MAPTKMT2A | |
| SCHEMBL11839367 | 0.80 | KMT2A (0.65) | CYP1A2HSD17B10MEN1MAPTKMT2A | |
| SCHEMBL11674611 | 0.80 | KMT2A (0.75) | CYP1A2HSD17B10TAS2R38MEN1MAPT | |
| SCHEMBL30703669 | 0.79 | HSD17B10 (1.00) | CYP1A2HSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL12133 | 0.79 | HSD17B10 (1.00) | CYP1A2HSD17B10MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | SPIRAL THERAPEUTICS INC. | 2023-09-21 | — | — | US | disclosed |
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| US-8143270-B2 | 2-amino 1H-in-imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143270-B2 | 2-amino 1H-in-imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090023720-A1 | 2-Amino 1H-Imidazo Ring Systems and Methods | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-22 | — | — | US | disclosed |
| US-20090023720-A1 | 2-Amino 1H-Imidazo Ring Systems and Methods | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-22 | — | — | US | disclosed |
| US-7087758-B2 | Quinoline inhibitors of hyaki and hyak3 kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20050043352-A1 | Quinoline inhibitors of hyaki and hyak3 kinases | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | disclosed |
| EP-0192464-B1 | TELLURIUM SALT FOG INHIBITING AGENTS FOR SILVER HALIDE PHOTOGRAPHY | EASTMAN KODAK COMPANY (US) | 1991-05-08 | — | — | EP | disclosed |
| EP-0198634-B1 | QUATERNIZED TELLURIUM SALT FOG INHIBITING AGENTS FOR SILVER HALIDE PHOTOGRAPHY | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1991-01-23 | — | — | EP | disclosed |
| US-4677202-A | Quaternized 2,1,4-benzoxatellurazinium and 2,1,4-naphthoxatellurazinium salt derivitives | EASTMAN KODAK COMPANY (US) | 1987-06-30 | — | — | US | disclosed |
| US-4661438-A | Quaternized tellurium salt fog inhibiting agents for silver halide photography | EASTMAN KODAK COMPANY (US) | 1987-04-28 | — | — | US | disclosed |
| EP-0201201-A2 | Amido substituted divalent chalcogenide fog inhibiting agents for silver halide photography | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1986-11-12 | — | — | EP | disclosed |
| EP-0198634-A2 | Quaternized tellurium salt fog inhibiting agents for silver halide photography | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1986-10-22 | — | — | EP | disclosed |
| EP-0192464-A2 | Tellurium salt fog inhibiting agents for silver halide photography | EASTMAN KODAK COMPANY (US) | 1986-08-27 | — | — | EP | disclosed |
| EP-0192466-A2 | Novel chalcogen heterocycles, processes for their preparation, and articles containing such heterocycles | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1986-08-27 | — | — | EP | disclosed |
| US-4581330-A | AROMATIC OXATELLURAZINIUM SALTS | EASTMAN KODAK COMPANY (US) | 1986-04-08 | — | — | US | disclosed |
| US-4576905-A | Photographically useful chalcogenazoles, chalcogenazolines, and chalcogenazolinium and chalcogenazolium salts | EASTMAN KODAK COMPANY (US) | 1986-03-18 | — | — | US | disclosed |
| EP-0138362-A2 | Photographic materials containing chalcogenazoles, chalcogenazolines and chalcogenazolinium and chalcogenazolium salts | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-04-24 | — | — | EP | disclosed |
| EP-0136847-A2 | Photographically useful chalcogenazolylidene and chalcogenazolium dyes and methods for their preparation | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1985-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043352-A1 | Quinoline inhibitors of hyaki and hyak3 kinases | HIPK3, HIPK1, HYPK | CYP1A2 3658/4885HSD17B10 1529/4885TAS2R38 2366/4885 |
| US-20090023720-A1 | 2-Amino 1H-Imidazo Ring Systems and Methods | IL2, IL2RA, IL4I1 | CYP1A2 1349/4885HSD17B10 4361/4885TAS2R38 2942/4885 |
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | OTC, SLC26A4, OAT | CYP1A2 985/4885HSD17B10 2300/4885TAS2R38 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.